Federal Appeals Court Reinstates Zyla Life Sciences’ Case Against Wells Pharma Over Unapproved Arthritis Treatment

The U.S. Court of Appeals for the Fifth Circuit has reinstated Zyla Life Sciences LLC’s legal action against Wells Pharma. This suit aims to prevent Wells Pharma from distributing rheumatoid arthritis suppositories that lack approval from the U.S. Food and Drug Administration. The court dismissed Wells Pharma’s defense, which claimed that Zyla’s allegations are overruled by federal statutes. Importantly, the Fifth Circuit highlighted that rejecting Zyla’s claims could lead to “staggering” consequences. Further details on this legal development can be found in the Law360 article.